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ABSTRACT 
 
Introduction: Baseline severity and clinical stroke syndrome (Oxford Community 
Stroke Project, OCSP) classification are predictors of outcome in stroke. We used data 
from the ‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST) to assess the 
relationship between stroke severity, early recovery, outcome and OCSP syndrome.  
 
Methods: TAIST was a randomised controlled trial assessing the safety and efficacy of 
tinzaparin versus aspirin in 1,484 patients with acute ischaemic stroke. Severity was 
measured as the Scandinavian Neurological Stroke Scale (SNSS) at baseline and days 
4, 7 and 10, and baseline OCSP clinical classification recorded: total anterior 
circulation infarct (TACI), partial anterior circulation infarct (PACI), lacunar infarct 
(LACI) and posterior circulation infarction (POCI). Recovery was calculated as change 
in SNSS from baseline at day 4 and 10. The relationship between stroke syndrome 
and SNSS at days 4 and 10, and outcome (modified Rankin scale at 90 days) were 
assessed. 
 
Results: Stroke severity was significantly different between TACI (most severe) and 
LACI (mildest) at all four time points (p<0.001), with no difference between PACI and 
POCI. The largest change in SNSS score occurred between baseline and day 4; 
improvement was least in TACI (median 2 units), compared to other groups (median 
3 units) (p<0.001). If SNSS did not improve by day 4, then early recovery and late 
functional outcome tended to be limited irrespective of clinical syndrome (SNSS, 
baseline: 31, day 10: 32; mRS, day 90: 4); patients who recovered early tended to 
continue to improve and had better functional outcome irrespective of syndrome 
(SNSS, baseline: 35, day 10: 50; mRS, day 90: 2).  
  
Conclusions: Although functional outcome is related to baseline clinical syndrome 
(best with LACI, worst with TACI), patients who improve early have a more favourable 
functional outcome, irrespective of their OCSP syndrome. Hence, patients with a TACI 
syndrome may still achieve a reasonable outcome if early recovery occurs. 
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INTRODUCTION 
Baseline stroke severity, as assessed using measures such as Scandinavian 
Neurological Stroke Scale (SNSS)1, 2 or National Institute Health Stroke Scale 
(NIHSS),3 4 is widely accepted as the strongest clinical predictor of outcome in stroke; 
severe stroke is associated with an increased risk of death, disability and length of 
hospital stay, and institutionalisation.3, 5-8 9 Similarly, severity, is also related to the 
early clinical course, with patients with severe stroke more likely to experience 
deterioration.10 In addition, recovery is observed later in severe stroke 11 and it has 
been postulated that the extent of intrinsic cerebral damage is reflected not only by 
the degree of impairment, but also in the length of time to improvement after 
stroke.12  
 
The importance of clinical history and examination, for evaluating stroke patients is 
well recognised,13 and stroke can be classified into four clinical syndromes, which have 
distinct natural histories: total anterior circulation syndrome (TACS), partial anterior 
circulation syndrome (PACS), lacunar syndrome (LACS) and posterior circulation 
syndrome (POCS). TACS is typically associated with greatest severity and worse 
outcome, PACS the highest risk of recurrence, whilst LACS has the mildest severity, 
and POCS the most favourable outcome.14 Clinical classification is also predictive of 
the risk of deterioration, with TACS having the greatest risk and LACS the least; 
deterioration is associated with a worse prognosis.15  
 
The relationship between clinical classification and degree and timing of stroke 
recovery is less clear, and has been further examined here using data from the 
‘Tinzaparin in Acute Ischaemic Stroke Trial’ (TAIST).16 
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METHODS 
 
Subjects 
TAIST compared the safety and efficacy of tinzaparin (low molecular weight heparin) 
given at high dose (175 anti-Xa IU/kg/day), tinzaparin at medium dose (100 anti-Xa 
IU/kg/day), and aspirin (300 mg od), in patients with acute ischaemic stroke. 
Subjects were included within 48 hours of stroke onset. Non-trial anti-platelets or 
anti-coagulants could not be given during the treatment period (10 days). 
Management of hypertension and other factors such as carotid stenosis was at the 
discretion of the local physician. All data were collected prospectively as part of the 
trial protocol. 
 
Clinical stroke classification 
Investigators prospectively recorded baseline clinical stroke syndrome as part of the 
trial protocol, and used the Oxford Community Stroke Project (OCSP) classification.14 
All patients had haemorrhagic stroke excluded on the basis of computed topographic 
(CT) head scan and therefore were classified as total anterior circulation infarct 
(TACI), partial anterior circulation infarct (PACI), lacunar infarct (LACI) and posterior 
circulation infarct (POCI). 
 
Recovery 
Severity/impairment was measured at four different time points: baseline, day 4, 7 
and 10 using the Scandinavian Neurological Stroke Scale (SNSS), which ranges from 
0 (most severe) to 58 (no deficit), with death recorded as –1. The rate of recovery 
was calculated as the change in SNSS at each time point. For comparison, patients 
were split into two groups: those who improved early (improvement ≥3 on SNSS 
between baseline and day 4); and those who did not; 3 points was chosen as this was 
the median change in SNSS at day 4. Day 4 was chosen as the largest change in 
SNSS occurred between baseline and day 4 and those with day 4 SNSS score missing 
were not categorised.. 
 
Outcomes 
Outcome was assessed using the modified Rankin Scale (mRS) and Barthel Index (BI) 
at day 90 and recorded by face-to-face interview. Discharge disposition was classified 
as patients own home or other (such as institution). 
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Events 
Adverse events were recorded prospectively as part of the trial protocol including 
neurological deterioration (ND, a decrease in SNSS ≥ 5 points), recurrent stroke (RS, 
either ischaemic, haemorrhagic or unclassified), venous thromboembolism (deep vein 
thrombosis and/or pulmonary embolism), and extracranial bleeding. Other events, 
such as pneumonia, and cardiac events (myocardial syndrome, dysrhythmia) were 
also recorded. Event rates at day 4 were analysed pooled for clinical classification and 
then by early improvers and non improvers. Whilst some patients had more than one 
adverse event, the categories ND, RS and HTI were considered exclusive. 
 
Statistical methods 
Data are given as frequency (%), mean (standard deviation) or median (interquartile 
range) as appropriate. Patient characteristics and prognostic factors were compared 
by OCSP subgroup, using Chi-square, Wilcoxon and t-tests. Area under the curve 
(AUC) was used to compare the patterns of recovery by group. Change in SNSS was 
calculated at each time point and compared using Kruskal-Wallis Test. The Wilcoxon 
test was used to compare outcome in those who improved early with those who did 
not within each OCSP group. All analyses were performed using SAS (SAS Inst., USA). 
Significance was taken at p<0.05 and 95% confidence intervals are given. 
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RESULTS 
 
Subjects 
Of 1,499 randomised patients, emerging exclusion criteria prevented treatment in 15, 
with analyses performed on the remaining 1,484 patients (figure 1). The baseline 
characteristics of included patients are shown in table 1. Similar numbers of patients 
had TACI and PACI, whilst few had a POCI. Those with POCI tended to be slightly 
younger, and TACI patients were older and more likely to be male. There was a higher 
frequency of atrial fibrillation in patients with TACI, whilst patients with LACI had 
increased frequency of diabetes, and baseline blood pressure was also the highest 
(table 1). Patients with TACI had the most severe stroke severity (median SNSS 22) 
and LACI the least (median SNSS 40).  
 
Recovery 
Stroke impairment differed significantly between TACI (most severe), PACI and POCI 
(intermediate) and LACI (mildest), at all four time points (mean AUC p<0.001) (figure 
2a). There was no difference in impairment between PACI and POCI. The greatest 
change in SNSS score occurred between baseline and day 4 (median improvement 3), 
with the least change in TACI (median 2) compared to PACI, LACI and POCI (median 
3) (p<0.001) (table 2). Patients who had not improved by day 4 (i.e. SNSS change 
<3) only had a limited improvement thereafter (median, baseline: 31, day 10: 32). In 
contrast, those who improved by day 4 (SNSS increased by ≥3) have a much greater 
improvement thereafter (median, baseline: 35, day 10: 50).  A similar pattern was 
still seen when sub dividing improvers and non-improvers by clinical syndrome; 
notably patients with TACI who improve by day 4 still had a comparable day 10 SNSS 
score to those PACI, LACI or POCI who had not improved (figure 2b). After day 4, 
there was no difference between clinical subgroups in the rate of recovery observed. 
 
Outcome 
The modified Rankin Scale and Barthel Index differed significantly between TACI and 
the other stroke syndromes, in both improvers and non-improvers (table 3). 
Improvers in each clinical group had a significantly better outcome at day 90 
compared to those who had not improved at day 4. These differences persisted after 
adjustment for age. Notably, TACI improvers had similar outcomes to PACI, POCI and 
LACI, who had not improved (table 3). Improvers were significantly more likely to be 
discharged home (81.5%) than non-improvers (66.3%) (p<0.001). 
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Adverse Events 
Neurological deterioration (ND) and recurrent stroke (RS, ischaemic or haemorrhagic) 
events were confined to non-improvers at day 4, whilst other events (such as cardiac 
events and VTE) occurred in both improvers and non-improvers (table 4). 
Deterioration occurred more frequently than recurrence; TACI patients had the 
highest frequency of both ND and RS in comparison to patients with LACI who had the 
lowest frequency (table 4). Similarly, patients with TACI had the highest rate of any 
adverse event whilst LACI had the lowest. 
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DISCUSSION  
In keeping with previous studies we have demonstrated that baseline severity varies 
between clinical stroke syndromes, being mildest in LACI and most severe in patients 
with TACI. That this difference in severity persists throughout the first 10 days post 
stroke has not been previously described. Perhaps unsurprisingly, the rate of recovery 
also varies between syndromes, again with LACI improving most and fastest and TACI 
least and slowest. 
 
In the first ten days, most recovery occurred early (by day 4), following which time 
recovery was more linear.6, 17 We therefore dichotomised patients into ‘improvers’ and 
‘non-improvers’, dependent on their rate of recovery at day 4, and the recovery 
patterns of these sub-groups were distinct from one another. Furthermore, early 
improvement was significantly associated with a good outcome. Spontaneous recovery 
and association with good outcome is well documented in stroke 17-19 although in 
comparison to this group of patients, previous studies included either only moderate19 
or very severe stroke.19 The relationship between early improvement and outcome, 
across the range of stroke severity studied here, in patients within each clinical 
syndrome has not previously been documented. Furthermore the changes seen here 
were modest (median change ≥ 3 SNSS points) yet were still associated with a 
clinically significant improvement in outcome.  
 
Unlike aetiological classification, which is dependent on the results of ancillary 
investigations,20 clinical classification is simple and can be performed with reasonable 
reliability on initial assessment of the patient.21 Similarly, the further assessment of 
impairment as a measure of recovery during the first week after stroke can 
strengthen ability to predict outcome.22 This makes the combination of clinical 
classification and monitoring of recovery an attractive tool, both clinically and for 
research where the ability to accurately predict recovery and outcome is key. This 
may be especially beneficial in subgroups of patients thought typically to have a 
poorer outcome, such as TACS, since there appears that there is at least one 
subgroup of patients who may do relatively well. 
 
Potential reasons for non improvement were analysed and were insufficient to account 
for lack of improvement in the majority of patients. However, recovery mechanisms 
are poorly understood and may relate to angiological factors, including spontaneous 
lysis, thrombus migration and transcortical perfusion networks,23 which were not 
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studied directly here. Beyond these vascular factors, recover may also be intrinsically 
linked to the brain’s plastic potential,24 not withstanding that certain events may 
intervene and prevent recovery. 
 
A caveat in our findings is that by assessing recovery in terms of severity (SNSS), 
multivariate analysis was not possible to ascertain if outcome was related to severity, 
as has been previously well documented. Furthermore, selection bias may have been 
present since we studied patients enrolled into the randomised trial; limited inclusion 
criteria will mean that some groups of patients were under represented (e.g. POCI) 
whilst the trial excluded patients with very minor or very severe strokes. Similarly, 
due to the long recruitment time window in TAIST (48 hours), stroke impairment will 
have changed in some patients prior to enrolment, and also patients who may have 
improved or deteriorated rapidly during the first hours will have been excluded. Future 
studies should focus on patients with hyperacute stroke. Despite this a large number 
of patients continue to present late to medical practitioners. Finally, limitations of 
clinical classification are well documented, 21 with concordance for the diagnosis of 
PACS less than for that for TACS and LACS.25 
 
Despite these points, TAIST contains high quality data on a large number of patients 
in a population where no treatment effect was observed, hence making it appropriate 
for hypothesis generating analyses. This study suggests that early recovery is related 
to clinical stroke syndrome, with LACI having the greatest recovery and most 
favourable outcome, and TACI having the least recovery and poorest outcome. 
However, significant recovery can occur in patients traditionally thought to have a 
poor prognosis, such as TACI and PACI, with clinically significant improvement in 
outcome. 
 
These data, if confirmed, suggest that early monitoring of recovery using a simple 
clinical classification and impairment scale such as OCSP and SNSS respectively, may 
help in predicting prognosis and possibly deciding which patients to recruit into trials.  
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TABLE 1 
 
Baseline characteristics by stroke type. Number (%), mean (standard deviation) or median (inter quartile range). 
 
 Total OCSP Classification P value 
  LACI TACI PACI POCI  
Subjects (%) 1484 422 (28.4) 523 (35.2) 473 (31.9) 66 (4.5)  
Age (years) 71.6 (11.0) 70.7 (11.1) 72.6 (11.0) 71.7 (10.6) 68.5 (11.2) 0.006 
Male (%) 807 (54.4) 233 (55.2) 283 (54.1) 249 (52.6) 42 (63.6) 0.39 
SNSS (median (IQR)) 34 (24-42) 40 (33-47) 22 (12-30) 37 (29-45) 40 (30-46) <0.0001 
Systolic BP (mmHg) 156.4 (22.8) 160.1 (22.6) 154.5 (22.1) 155.4 (23.7) 156.2 (20.5) 0.001 
Diastolic BP (mmHg) 84.6 (12.1) 86.0 (12.1) 84.3 (12.3) 83.9 (12.0) 83.5 (11.3) 0.05 
Previous stroke (%) 192 (13.2) 52 (12.4) 66 (12.8) 67 (14.5) 8 (12.1) 0.82 
Previous TIA (%) 241 (16.3) 71 (16.9) 73 (14.7) 86 (18.2) 11 (16.7) 0.46 
Atrial fibrillation (%) 181 (21.4) 21 (9.1) 109 (32.8) 48 (20.0) 3 (7.1) <0.0001 
Diabetes (%) 250 (16.9) 91 (21.6) 81 (15.5) 67 (14.2) 11 (16.7) 0.02 
Previous MI (%) 232 (15.6) 62 (14.7) 90 (17.6) 70 (14.8) 10 (15.2) 0.62 
BP: blood pressure; MI: myocardial syndrome; SNSS: Scandinavian Neurological Stroke Scale; TIA: transient ischaemic attack 
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TABLE 2 
 
Rates of recovery by OCSP classification. Median (inter quartile range); comparison by the Kruskal-Wallis Test. 
 
 Total LACI TACI PACI POCI P value 
Change baseline – Day 4 3 (0 - 7) 3 (0 - 7) 2 (-2 - 6) 3 (0 - 7) 3 (-1 - 9) 0.001 
Change Day 4 - Day 7 2 (0 - 4) 2 (0 - 4) 2 (0 - 4) 2 (0 - 4) 0 (0 - 4) 0.06 
Change Day 7 – Day 10 0 (0 - 3) 1 (0 - 3) 0 (0 - 3) 0 (0 - 3) 1 (0 - 3) 0.08 
Change baseline – Day 10 6 (2 – 12) 7 (3 – 11) 6 (0 – 12) 7 (2 – 12) 6 (0.5 – 12) 0.08 
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TABLE 3 
 
Outcome at day 90 by stroke type and type of recovery. Median (inter quartile range); comparison by the Wilcoxon test. 
 
 Early improvers Non improvers P value 
Rankin Scale    
LACI 2 (1 - 3) 3 (2 - 4) <0.0001 
TACI 3 (2 - 4) 4 (4 - 6) <0.0001 
PACI 2 (1 - 3) 3 (3 - 2) <0.0001 
POCI 2 (1 - 3) 3 (2 - 5) 0.002 
Barthel Index    
LACI 95 (85 - 100) 85 (60 - 95) <0.0001 
TACI 85 (35 - 100) 22 (- 5 - 65) <0.0001 
PACI 97.5 (85 - 100) 70 (40 - 90) <0.0001 
POCI 100 (87.5 - 100) 60 (0 - 95) 0.001 
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TABLE 4 
 
Adverse events at day 4 by improver/non improver status and clinical classification. Those with day 4 SNSS score missing were 
not categorised. Some patients had more than one event. Number (%).  
 
 Improvers Non improvers 
 Total 
732 
LACI 
216 
TACI 
224 
PACI 
256 
POCI 
36 
Total 
703 
LACI 
187 
TACI 
289 
PACI 
197 
POCI 
30 
Neurological deterioration  0 0 0 0 130(18.5) 20(10.7) 71 (24.6) 32 16.2) 7 (23.3) 
Extracranial bleeding 27(3.7) 8(3.7) 11(4.9) 6 (2) 2 (5.6) 36 (5.1) 11 (5.9) 12 (4.1) 9 (4.6) 4 (13.3) 
VTE 2 (0.3) 0 1 (0.4) 1 (0.4) 0 10 (1.4) 1 (0.5) 5 (1.7) 4 (2.0) 0 
Recurrent stroke* 0 0 0 0 0 31 (4.4) 4 (2.1) 15 (5.2) 11 (5.6) 1 (3.3) 
Haemorrhagic stroke 0 0 0 0 0 9 (1.3) 0 7 (2.4) 2 (1.0) 0 
Pneumonia 0 0 0 0 0 10 (1.4) 2 (1.1) 7 (2.4) 1 (0.5) 0 
Cardiac events 6 (0.8) 0 1 (0.4) 3 (1.2) 2 (5.6) 17 (2.4) 3 (1.6) 8 (2.8) 6 (3.0) 0 
HTI 2 (0.3) 0 1 (0.4) 0 1 (2.7) 1 (0.1) 0 0 1 (0.5) 0 
Others 4 (0.5) 0 2 (0.9) 2 (0.8) 0 11 (1.7) 3 (1.6) 6 (2.1) 2 (1.0) 0 
Any event 41(5.6) 8(3.7) 16(7.1) 12(4.7) 4(11.1) 163(23.2) 44 (23.5) 138 (47.8) 69 (35.0) 12 (40.0) 
*Ischaemic or unclassified, VTE venous thromboembolism, HTI haemorrhagic transformation of infarction 
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FIGURE 1 
 
Number of patients included in the analysis. Improvers have a change in SNSS 
between baseline and day 4 of greater than or equal to 3 points. Those with day 4 
SNSS score missing were not categorised. 
 
Randomised into TAIST
n = 1,499
Excluded from analysis:
Emerging exclusion criteria
Did not receive treatment
n = 15
Included in analysis
n = 1,484
LACI: n = 422
Improvers: 216
Non improvers: 187
PACI: n = 473
Improvers: 256
Non improvers: 197
TACI: n = 523
Improvers: 224
Non improvers: 289
POCI: n = 66
Improvers: 36
Non improvers: 30
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FIGURE 2a 
 
Recovery by clinical stroke syndrome 
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FIGURE 2b 
SNSS at days 0, 4, 7, 10 by early improvement and stroke syndrome, broken lines indicate patients who had not improved to 
median of 3 SNSS points by day 4. 
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